Pay in 4 interest-free payments of $5.98 Learn more
Ships within 48 hours · Estimated delivery Aug 20 - Aug 25
This material is not a medicine, food, supplement, or cosmetic
insert the needle at 4590 into subcutaneous tissue [6]
Allison Whitten Pfizer's LITFULO meets primary endpoints in Phase 3 vitiligo trials Pfizer reported topline results from two Phase 3 trials of LITFULO (ritlecitinib) in nonsegmental vitiligo, with both the 50 and 100 milligram once-daily doses meeting co-primary endpoints for facial and total body repigmentation over placebo at Week 52
PMC 5333585
States with more restrictive compounding regulations may prohibit it entirely
DOI: 10.1161/CIRCRESAHA.118.312498 PMC Review (2025) PMC12177089 Comprehensive mechanistic review confirming NAD+ as a critical coenzyme for mitochondrial function across de novo synthesis, Preiss-Handler, and salvage biosynthetic pathways
